Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?

References

• Shah RB, Mehra R, Chinnaiyan AM et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res.64, 9209–9216 (2004).
   PubMed Web of Science ®Google Scholar
• Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res.12, 1665–1671 (2006).
   PubMed Web of Science ®Google Scholar
• Kim JH, Dhanasekaran SM, Mehra R et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res.67, 229–239 (2007).
   Google Scholar
• Slovin SF. How to channel a minimal response for maximal outcome. Curr. Opin. Urol.16, 179–185 (2006).
   Google Scholar
• Slovin SF, Ragupathi G, Adluri S et al. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo hexasaccharide conjugate in man. Proc. Natl Acad. Sci. USA6, 5710–5715 (1999).
   Google Scholar
• Slovin SF, Ragupathi G, Musselli C et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with α-N-acetylgalactosamine-o-serine/threonine (Tn) conjugate Vaccine J. Clin. Oncol.21, 4292–4298 (2003).
   PubMed Web of Science ®Google Scholar
• Slovin SF, Ragupathi G, Fernandez C et al. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 or QS-21. Vaccine23, 3114–3122 (2005).
   Google Scholar
• Slovin SF, Ragupathi G, Fernandez C et al. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol. Immunother.54, 694–702 (2005).
   PubMed Web of Science ®Google Scholar
• Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA281, 1591–1597 (1999).
   PubMed Web of Science ®Google Scholar
• Slovin SF, Ragupathi G, Fernandez C, Diani M et al. A polyvalent vaccine for high risk prostate patients. Are more antigens better? Cancer Immunol. Immunother.56, 1921–1930 (2007).
   PubMed Web of Science ®Google Scholar
• Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res.62, 5770–5777 (2002).
   PubMed Web of Science ®Google Scholar
• Eder JP, Kantoff PW, Roper K et al. A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res.6, 1632–1638 (2000).
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Wang W, Manola J et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol.22, 2122–2132 (2004).
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Wang W, Manola J et al. Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: follow-up clinical results from ECOG 7897. J. Clin. Oncol.23(Suppl. 16), (2005) (Abstract 4501).
   Google Scholar
• Hodge JW, Sabzevari H, Yafal AG et al. A triad of costimulatory molecules synergizes to amplify T-cell activation. Cancer Res.59, 5800–5807 (1999).
   PubMed Web of Science ®Google Scholar
• Gulley J, Todd N, Dahut W et al. A Phase II study of PROSTVAC-VF vaccine, and the role of GM-CSF, in patients (pts) with metastatic androgen insensitive prostate cancer (AIPC). J. Clin. Oncol.23(Suppl. 16), (2005) (Abstract 2504).
   Google Scholar
• Kantoff PW, Globe LM, Tannenbaum SI et al. Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC). J. Clin. Oncol.24(Suppl. 18), (2006) (Abstract 2501).
   Google Scholar
• Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin. Cancer Res.13, 3776–3782 (2007).
   PubMed Web of Science ®Google Scholar
• Arlen PM, Skarupa L, Pazdur M et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J. Urol.178, 1515–1520 (2007).
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific and long-lasting antitumor immunity. Proc. Natl Acad. Sci. USA90, 3539–3543 (1993).
   PubMed Web of Science ®Google Scholar
• Eager R, Nemunaitis. GM-CSF gene-transduced tumor vaccines. Mol. Ther.12, 18–27 (2005).
   PubMed Web of Science ®Google Scholar
• Simons JW, Mikhak B, Chang J-F et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res.59, 5160–5168 (1999).
   PubMed Web of Science ®Google Scholar
• Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res.57, 1537–1546 (1997).
   PubMed Web of Science ®Google Scholar
• Berns AJ, Clift S, Cohen LK et al. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum. Gene Ther.6, 347–368 (1995).
   Google Scholar
• Simons JW, Carducci MA, Mikhak B et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin. Cancer Res.12, 3394–3401 (2006).
   PubMed Web of Science ®Google Scholar
• Small EJ, Sacks N, Nemunaitis J et al. Granulocyte macrophage colony-stimulating factor – secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res.13, 3883–3891 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas-Kaskel A-K, Zeiser R, Jochim R et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int. J. Cancer119, 2428–2434 (2006).
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi O, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol.18, 3894–3903 (2000).
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol.24, 3089–3094 (2006).
   PubMed Web of Science ®Google Scholar
• Leach DM, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science271, 1734–1736 (1996).
   PubMed Web of Science ®Google Scholar
• Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte antigen-4(CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc. Natl Acad. Sci. USA96, 8603–8608 (1999).
   PubMed Web of Science ®Google Scholar
• Kwon ED, Foster BA, Hurwitz AA et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl Acad. Sci. USA96, 15074–15079 (1999).
   PubMed Web of Science ®Google Scholar
• Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity inpatients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol.12, 1005–1016 (2005).
   PubMed Web of Science ®Google Scholar
• Blansfield JA, Beck KE, Tran K et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother.28, 593–598 (2005).
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol.23, 6043–6053 (2005).
   PubMed Web of Science ®Google Scholar
• Hurwitz AA, Sullivan TJ, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen 4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc. Natl Acad. Sci. USA99, 3013–3017 (2002).
   Google Scholar
• van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-CTLA-4 and GM-CSF producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med.190, 355–366 (1999).
   PubMed Web of Science ®Google Scholar
• van Elsas A, Sutmuller RP, Hurwitz AA. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med.194, 481–489 (2001).
   PubMed Web of Science ®Google Scholar
• Camacho LH, Ribas A, Glaspy JA et al. Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol.22(Suppl. 164) (2004) (Abstract 2505).
   Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA100(8), 4712–4717 (2003).
   PubMed Web of Science ®Google Scholar
• Gerritsen W, Van Den Eertwegh AJ, De Gruijl T et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patient with hormone-refractory prostate cancer (mHRPC). Proc. Am. Soc. Clin. Oncol.24(Suppl. 100) (2006) (Abstract 2500).
   Google Scholar
• Sharp HJ, Wansley EK, Garnett T et al. Synergistic antitumor activity of immune strategies combined with radiation. Front. Biosci.12, 4900–4910 (2007).
   PubMed Web of Science ®Google Scholar